| Autor: |
Ruiz I; Pharmacy, 21668University of Maryland Medical Center, Baltimore, MD, USA., Sparkes T; Pharmacy, 21668University of Maryland Medical Center, Baltimore, MD, USA., Masters B; Pharmacy, 21668University of Maryland Medical Center, Baltimore, MD, USA., Barth R; Surgery, 21668University of Maryland Medical Center, Baltimore, MD, USA., Maluf D; Surgery, 21668University of Maryland Medical Center, Baltimore, MD, USA., Freedman S; Pharmacy, 21668University of Maryland Medical Center, Baltimore, MD, USA. |
| Abstrakt: |
Introduction: The occurrence of simultaneous liver kidney transplantation has greatly increased; however, the ideal induction and maintenance immunosuppression remains unknown. Question: This evaluation aimed to determine if corticosteroid only induction in simultaneous liver kidney transplant recipients provided adequate prophylaxis against rejection when compared to basiliximab. Design: This was a single center, retrospective, cohort study of adult simultaneous liver kidney transplant recipients from June 2010 to June 2019 receiving corticosteroid only (N = 41) or basiliximab (N = 42) induction. Results: Liver or kidney biopsy proven acute rejection at 3 months was comparable between the corticosteroid only and basiliximab groups (10% vs 7%, P = .67), which persisted through 12 months posttransplant (15% vs 21%, P = .42). The occurrence of any infection at 3 months was increased in the corticosteroid only group relative to the basiliximab group (41% vs 21%, P = .049). Graft and patient survival at 12 months were similar between groups. Maintenance immunosuppression was overall minimized with a tacrolimus goal of 6-8 ng/mL, mycophenolate mofetil dose reduction to 1000 mg/day by 3 months, and early steroid withdrawal in both groups. Conclusion: Our findings suggested that corticosteroid only induction was an effective strategy for preventing rejection in simultaneous liver kidney transplant recipients, even in combination with reduced maintenance immunosuppression. |
